Who Says There is No Money in Making Vaccines? At Least $5.7 Billion Given to Vaccine Manufacturers in 2011 by US Gov’t
In 2011, the US Federal government awarded 6 pharmaceutical corporations over $5.7 Billion to manufacture vaccines children’s vaccines alone.
. . . . Rob Evans and Sarah Boseley guardian.co.uk 04/11/2010 The pharmaceutical firms Novartis and Roche have threatened to pull out of Britain and relocate thousands of jobs abroad, in an ongoing row over pricing for the NHS and rules surrounding safety trials. The Swiss drug companies made their threats known in personal meetings…
Source: AFP BASEL, Switzerland â€” The head of Swiss pharmaceutical giant Novartis on Tuesday warned that governments now trying to cancel swine flu vaccine contracts might not be dealt with so swiftly in the next pandemic. Chairman and chief executive Daniel Vasella said those that had been reliable partners would be favoured. “The same governments…
Swiss pharmaceutical group Novartis on Monday denied that it faced hurdles in gaining regulatory approval in Switzerland for one of its swine flu vaccines because of possible bacterial contamination.
Withholding this information from volunteers violates informed consent standards upheld by the Nuremberg Code.
FDA approves Swine Vax prior to Some Clinical Safety Trials Beginning.
The new manufacturing process for flu shots, called cell-line technologies, are little understood and have the potential for serious, long term consequences.
Medical Mafia’s propaganda blitz was successful, and over a million previously healthy and happy American citizens were hypnotized and terrorized into placing the vaccine toxins into their bloodstreams.
Starting with this excellent synopsis of the evidence, in their own words, of the genocidal intent of the global cabal, which will soon be unleashed bigtime with the WHO Flu vaccine….
Racing to produce a huge quantity of vaccine to fight an expected tsunami of swine flu cases this fall, Novartis says that a single low dose of its Celtura jab produced an immune response sufficient to protect the volunteers enrolled in a small trial.
Page 1 of 2